We are live on ! Find out more
NMTR

9 Meters Biopharma
NMTR

Delisted

NMTR was delisted on the 25th of July, 2023.

Back to rankings

36 hedge funds and large institutions have $46.7M invested in 9 Meters Biopharma in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

452% more call options, than puts

Call options by funds: $1.85M | Put options by funds: $335K

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

140% more funds holding

Funds holding: 15 → 36 (+21)

92% more capital invested

Capital invested by funds: $24.3M → $46.7M (+$22.5M)

Holders
36
Holders Change
+21
Holders Change %
+140%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
6
Reduced
1
Closed
6
Calls
$1.85M
Puts
$335K
Net Calls
+$1.51M
Net Calls Change
+$1.51M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$16.2M
2
State Street
State Street
Massachusetts
+$2.74M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.22M
4
Bank of America
Bank of America
North Carolina
+$1.02M
5
TCIM
TIAA CREF Investment Management
New York
+$927K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$3.52M
2
Millennium Management
Millennium Management
New York
-$2.09M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.3M
4
ECM
Element Capital Management
New York
-$580K
5
BCM
BlueCrest Capital Management
Jersey
-$315K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$62K +$48.6K +132 New
CG
27
Cutler Group
California
$58K +$46K +125 New
AIP
28
Ameritas Investment Partners
Nebraska
$34K +$26.9K +73 New
Barclays
29
Barclays
United Kingdom
$33K +$25.8K +70 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$25K +$19.1K +52 New
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$14.3K +$11K +30 New
IA
32
IFP Advisors
Florida
$12K +$5.89K +16 +160%
PIA
33
Piedmont Investment Advisors
North Carolina
$8K +$5.89K +16 New
MAM
34
Meeder Asset Management
Ohio
$5.75K +$4.42K +12 New
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$3K +$2.58K +7 New
IP
36
Intellectus Partners
California
$2K – – –
Goldman Sachs
37
Goldman Sachs
New York
– -$3.52M -6,426 Closed
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
– -$1.3M -3,524 Closed
ECM
39
Element Capital Management
New York
– -$580K -1,059 Closed
BCM
40
BlueCrest Capital Management
Jersey
– -$315K -575 Closed
Jane Street
41
Jane Street
New York
– -$214K -392 Closed
RPG
42
Risk Paradigm Group
Texas
– -$27.4K -50 Closed
1
2

NMTR Hedge Fund Activity: Q2 2018 in Review

36 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2018, worth a combined $46.7M — up 92% from $24.3M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new NMTR positions and 6 closed out — a net gain of 21 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $16.2M. The largest seller was Goldman Sachs, exiting entirely with an estimated $3.52M sold.

  • 36 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2018, up from 15 in Q1 2018.
  • Funds reported $46.7M of 9 Meters Biopharma stock for Q2 2018, up 92% quarter-over-quarter.
  • 27 funds opened new 9 Meters Biopharma positions in Q2 2018 and 6 closed out, a net change of +21 holders.
  • The largest 9 Meters Biopharma buyer in Q2 2018 was BlackRock, an estimated $16.2M added.
  • The largest 9 Meters Biopharma seller in Q2 2018 was Goldman Sachs, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2018.